To investigate if BRD9 inhibition can also affect other nonoverlapping CSC populations, we used flow cytometry analyses of CSC marker expression in PDAC cell lines and PDAC patient-derived primary tumor samples. The gene discussed is BRD9; the disease is neoplasm.